雄激素剥夺联合多西他赛及雄激素受体信号抑制剂三联疗法治疗转移性去势敏感性前列腺癌:荟萃分析
该系统评价与荟萃分析检索MEDLINE/PubMed、Cochrane图书馆及ASCO会议摘要,纳入5项在接受了多西他赛的mCSPC患者中评估ARSi联合ADT的随机对照试验;结果显示三联疗法较ADT联合多西他赛改善总生存(HR=0.73,p<0.00001),ARSi与化疗同期给药时及新发mCSPC亚组中均维持生存获益。
要点
- 三联疗法较ADT联合多西他赛改善mCSPC患者总生存,HR=0.73(p<0.00001)
- ARSi与化疗同期给药时OS获益维持(HR=0.72,p<0.00001),序贯给药未见统计学效应(p=0.44)
- 新发mCSPC亚组中三联疗法显著改善OS(HR=0.72,p<0.0001)
核心结论
- 在接受了多西他赛的mCSPC患者中,ADT基础上加用ARSi具有明确的生存优势,尤其在ARSi与化疗同期给药时及新发mCSPC亚组中。
研究设计与样本
- 系统评价与荟萃分析,检索MEDLINE/PubMed、Cochrane图书馆及ASCO会议摘要,纳入5项随机对照试验。
- 纳入标准为在接受多西他赛的mCSPC男性中测试ARSi联合ADT的随机对照试验。
- 数据提取按PRISMA声明进行,汇总风险比采用随机或固定效应模型计算,统计分析使用RevMan软件(v.5.2.3)。
主要发现
- 三联疗法较ADT联合多西他赛改善mCSPC患者总生存,HR=0.73(p<0.00001)。
- ARSi与化疗同期给药时维持OS获益,HR=0.72(p<0.00001)。
- ARSi序贯于多西他赛后给药时未检测到统计学效应(p=0.44)。
- 新发mCSPC男性亚组中三联疗法显著改善OS,HR=0.72(p<0.0001)。
局限性
- 无法获取原始数据是本分析的主要局限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The addition of either docetaxel or an androgen receptor signalling pathway inhibitor (ARSi) to androgen-deprivation therapy (ADT) has become the standard of care for metastatic castration-sensitive prostate cancer (mCSPC) patients. Recent phase III data support even greater survival impact of a triplet regimen with ADT plus docetaxel plus an ARSi (abiraterone or darolutamide) compared to ADT plus docetaxel. OBJECTIVE: To evaluate whether the addition of an ARSi to ADT improves outcomes of mCSPC patients treated with docetaxel. METHODS: We searched MEDLINE/PubMed, the Cochrane Library, and ASCO Meeting abstracts for randomised clinical trials (RCTs) testing the combination of ARSi + ADT in mCSPC men who received docetaxel. Data extraction was conducted according to the PRISMA statement. Summary hazard ratio (HR) was calculated using random- or fixed-effects models. The statistical analyses were performed with RevMan software (v.5.2.3). RESULTS: Five RCTs were selected. Triplet therapy improved overall survival (OS) compared to ADT + docetaxel in mCSPC patients (HR = 0.73; p < 0.00001). This intensified strategy maintained the OS benefit when the ARSi was administered concomitant to chemotherapy (HR = 0.72; p < 0.00001), but no statistical effect was detected if the ARSi was sequential to docetaxel (p = 0.44). Moreover, in the subgroup of men with de novo mCSPC, triplets significantly improved OS (HR = 0.72, p < 0.0001). The lack of access to raw data was the main limit of our analysis. CONCLUSION: Our results support a clear survival advantage of adding an ARSi to ADT in mCSPC patients treated with docetaxel, mainly when the ARSi was administered concomitantly to chemotherapy and in the subgroup of de novo mCSPC.
引用
- Ciccarese C, Iacovelli R, Sternberg CN, et al. Triplet therapy with androgen deprivation, docetaxel, and androgen receptor signalling inhibitors in metastatic castration-sensitive prostate cancer: A meta-analysis. Eur J Cancer. 2022. PMID: 35964470. doi:10.1016/j.ejca.2022.07.011
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。